pembrolizumab plus paclitxel followed by doxorubicin plus cyclophosphamide
pembrolizumab plus SoC
Comparator:
vs placebo; vs paclitaxel followed by doxorubicin plus cyclophosphamide; vs placebo plus SoC; vs Standard of Care (SoC);
Risk of bias:
low;
some concerns;
high;
NA;